Integrated Investment Consultants’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $961K | Buy |
15,841
+275
| +2% | +$16K | 0.2% | 78 |
|
|
2025
Q4 | $840K | Buy |
15,566
+5,679
| +57% | +$273K | 0.16% | 96 |
|
|
2025
Q3 | $446K | Buy |
9,887
+400
| +4% | +$18.7K | 0.08% | 166 |
|
|
2025
Q2 | $439K | Sell |
9,487
-25
| -0.3% | -$1.23K | 0.09% | 157 |
|
|
2025
Q1 | $580K | Sell |
9,512
-13,361
| -58% | -$779K | 0.12% | 134 |
|
|
2024
Q4 | $1.29M | Sell |
22,873
-315,245
| -93% | -$17.6M | 0.27% | 70 |
|
|
2024
Q3 | $774K | Buy |
+338,118
| New | +$15.9M | 0.17% | 90 |
|
|
2023
Q4 | – | Sell |
-3,798
| Closed | -$220K | – | 237 |
|
|
2023
Q3 | $220K | Sell |
3,798
-1,078
| -22% | -$66.1K | 0.08% | 204 |
|
|
2023
Q2 | $312K | Sell |
4,876
-604
| -11% | -$40.5K | 0.1% | 180 |
|
|
2023
Q1 | $380K | Buy |
5,480
+1,288
| +31% | +$90.8K | 0.12% | 153 |
|
|
2022
Q4 | $302K | Buy |
4,192
+245
| +6% | +$18.5K | 0.1% | 175 |
|
|
2022
Q3 | $281K | Sell |
3,947
-323
| -8% | -$23.4K | 0.11% | 164 |
|
|
2022
Q2 | $329K | Sell |
4,270
-215
| -5% | -$16.4K | 0.12% | 140 |
|
|
2022
Q1 | $328K | Buy |
4,485
+364
| +9% | +$24.4K | 0.09% | 207 |
|
|
2021
Q4 | $257K | Sell |
4,121
-287
| -7% | -$16.8K | 0.07% | 255 |
|
|
2021
Q3 | $261K | Buy |
4,408
+92
| +2% | +$6.06K | 0.08% | 232 |
|
|
2021
Q2 | $288K | Buy |
4,316
+516
| +14% | +$33.6K | 0.08% | 215 |
|
|
2021
Q1 | $240K | Buy |
3,800
+340
| +10% | +$21.2K | 0.08% | 219 |
|
|
2020
Q4 | $215K | Buy |
+3,460
| New | +$213K | 0.08% | 219 |
|
|
2020
Q3 | – | Sell |
-3,615
| Closed | -$213K | – | 203 |
|
|
2020
Q2 | $213K | Hold |
3,615
| – | – | 0.1% | 150 |
|
|
2020
Q1 | $202K | Sell |
3,615
-1,809
| -33% | -$111K | 0.12% | 132 |
|
|
2019
Q4 | $348K | Sell |
5,424
-75
| -1% | -$4.29K | 0.14% | 104 |
|
|
2019
Q3 | $279K | Buy |
+5,499
| New | +$258K | 0.14% | 110 |
|
|
2018
Q2 | – | Sell |
-3,433
| Closed | -$217K | – | 232 |
|
|
2018
Q1 | $217K | Buy |
+3,433
| New | +$221K | 0.09% | 164 |
|
|
2017
Q3 | $200K | Buy |
3,130
+130
| +4% | +$7.59K | 0.09% | 157 |
|
|
2017
Q2 | $167K | Hold |
3,000
| – | – | 0.08% | 183 |
|
|
2017
Q1 | $163K | Hold |
3,000
| – | – | 0.07% | 186 |
|
|
2016
Q4 | $175K | Hold |
3,000
| – | – | 0.08% | 165 |
|
|
2016
Q3 | $151K | Hold |
3,000
| – | – | 0.08% | 183 |
|
|
2016
Q2 | $221K | Sell |
3,000
-1,000
| -25% | -$70.7K | 0.13% | 112 |
|
|
2016
Q1 | $264K | Buy |
+4,000
| New | +$252K | 0.15% | 93 |
|
Other funds holding BMY
VCM
VPM
Integrated Investment Consultants's BMY Position: Q1 2026 in Review
Integrated Investment Consultants increased its Bristol-Myers Squibb (BMY) stake by 1.8% in Q1 2026, buying an estimated $16K and bringing the position to 15,841 shares worth $961K. The position accounts for 0.2% of the portfolio, ranked #78.
Integrated Investment Consultants first reported a position in BMY in Q1 2016 and has held it in 31 quarters since. The position peaked at $1.29M in Q4 2024. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Integrated Investment Consultants held 15,841 shares of Bristol-Myers Squibb worth $961K as of Q1 2026.
- Integrated Investment Consultants bought 275 Bristol-Myers Squibb shares in Q1 2026, an estimated $16K.
- Bristol-Myers Squibb made up 0.2% of Integrated Investment Consultants's portfolio in Q1 2026, its #78 holding.
- Integrated Investment Consultants first reported a position in Bristol-Myers Squibb in Q1 2016 and has held it in 31 quarters since.
- Integrated Investment Consultants's Bristol-Myers Squibb position peaked at $1.29M in Q4 2024.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Integrated Investment Consultants's 13F filing for Q1 2026, filed 1 Jun 2026.